Celularity Inc. (NASDAQ:CELUW – Get Rating) was the recipient of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 7,300 shares, a decline of 60.1% from the February 13th total of 18,300 shares. Based on an average daily trading volume, of 14,600 shares, the short-interest ratio is currently 0.5 days.
Celularity Trading Up 14.3 %
NASDAQ:CELUW traded up $0.01 during trading hours on Friday, hitting $0.08. 82,509 shares of the company's stock traded hands, compared to its average volume of 17,187. Celularity has a twelve month low of $0.06 and a twelve month high of $1.99. The stock has a fifty day moving average price of $0.09.
Get Celularity alerts:Celularity Company Profile
(Get Rating)
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.
Featured Stories
- Get a free copy of the StockNews.com research report on Celularity (CELUW)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.